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Objective: Dapagliﬂozin is a highly selective, orally
active inhibitor of renal sodium-glucose cotransporter
2 that reduces hyperglycemia by increasing urinary
glucose excretion. The goal of this study was to
evaluate dapagliﬂozin as monotherapy in drug-naive
Asian patients with type 2 diabetes whose disease was
inadequately controlled with diet and exercise.
Methods: In this Phase III, multicenter, parallel-
group, double-blind study, drug-naive patients with
glycosylated hemoglobin (HbA1c) levels Z7.0% to
r10.5% (Z53–r91 mmol/mol) were randomized
(by using an interactive voice response system) to
receive placebo (n ¼ 132), dapagliﬂozin 5 mg (n ¼ 128),
or dapagliﬂozin 10 mg (n ¼ 133). The primary end
point was mean change from baseline in HbA1c level
at week 24 (last-observation-carried-forward). Secon-
dary end points included changes in fasting plasma
glucose, 2-hour postprandial glucose, body weight,
and other glycemic parameters.
Results: Baseline characteristics were balanced
across groups. Most patients (89%) were Chinese,
median disease duration was 0.2 year, and mean
HbA1c level was 8.26%. Most patients (87%) com-
pleted the study. At week 24, mean reductions in
HbA1c were 0.29% for placebo versus 1.04% and
1.11% for dapagliﬂozin 5 and 10 mg, respectively
(P o 0.0001 for both doses). Changes in fasting
plasma glucose were 2.5, 25.1, and –31.6 mg/dL
(0.14, 1.39, and 1.75 mmol/L) for placebo, dapa-
gliﬂozin 5 mg, and dapagliﬂozin 10 mg. Changes in
2-hour postprandial glucose were 1.1, 46.8, and 54.9
mg/dL (0.06, 2.60, and 3.05 mmol/L). Reductions in84body weight were 0.27, 1.64, and 2.25 kg.
Proportions of patients achieving HbA1c levels o7.0%
(53 mmol/mol) were 21.3%, 42.6%, and 49.8%. Ad-
verse events (AEs) occurred in 63.6%, 61.7%, and
60.9% of patients, and serious AEs occurred in 1.5%,
3.9%, and 3.0% of patients. No deaths occurred.
Hypoglycemia was uncommon (1.5%, 0.8%, and
0.8%); no hypoglycemic event led to discontinuation.
Genital infections occurred in 0.8%, 3.1%, and 4.5% of
patients and urinary tract infections in 3.0%, 3.9%, and
5.3% of patients. No AEs of renal infection or pyelo-
nephritis were reported. No changes in renal function or
AEs of renal failure occurred.
Conclusions: Compared with placebo, dapagliﬂo-
zin 5 and 10 mg demonstrated clinically and statisti-
cally signiﬁcant improvements in HbA1c levels after 24
weeks of treatment. Dose-dependent, statistically sig-
niﬁcant reductions in fasting plasma glucose, post-
prandial glucose, and weight were also observed for
both doses compared with placebo. AEs and serious
AEs were balanced across groups, with low rates of
hypoglycemia and no increase in renal events. Genital
infections and urinary tract infections were more
common with dapagliﬂozin. Dapagliﬂozin as mono-
therapy in these drug-naive Asian patients was wellVolume 36 Number 1
L. Ji et al.tolerated, signiﬁcantly improving glycemic control
with the additional beneﬁt of weight loss. (Clin Ther.
2014;36:84–100) & 2014 The Authors. Published by
Elsevier, Inc.
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As the global burden of diabetes increases, Asian
countries in particular are experiencing a pronounced
rise in the number of patients with type 2 diabetes
mellitus (T2DM). As recently as 1978, diabetes was
considered a rare disease in Asia, with an estimated
prevalence of just 0.6% in China.1 A large-scale,
Chinese survey conducted from June 2007 to May
2008 estimated that the overall prevalence of diabetes
(including both type 1 and 2 disease, diagnosed and
undiagnosed cases) was now closer to 10%,
translating into 490 million adults.2 The increase in
T2DM speciﬁcally is believed to be due to unhealthy
lifestyle changes associated with recent and rapid
socioeconomic development,3 in addition to genetic
determinants.4 Furthermore, the 150 million adults
in China with prediabetes (ie, impaired fasting gluc-
ose) represent a substantial at-risk population for an
increasing T2DM burden in Asia in the future.2,3
Faced with this increasing global burden of disease,
the treatment of T2DM presents a number of con-
tinuing challenges.5 Due to the progressive nature of
T2DM, treatment intensiﬁcation is frequently required
to maintain glycemic control.6 However, many of the
currently available therapies are associated with adverse
effects such as hypoglycemia and weight gain,
highlighting the unmet need for novel agents with an
improved risk/beneﬁt proﬁle.
Dapagliﬂozin is a novel, highly selective, orally
active inhibitor of renal sodium-glucose cotransporter
2 (SGLT2) that has recently been approved for the
treatment of adult patients with T2DM in several
European Union countries, Australia, Brazil, Mexico,
and Ukraine. Under normal physiological conditions,
glucose is freely ﬁltered in renal glomeruli and reab-
sorbed in the proximal tubules via SGLT2 (and to a
lesser extent by SGLT1). Through its inhibition of
SGLT2, dapagliﬂozin decreases renal glucose reab-
sorption, which in turn leads to a reduction in hyper-
glycemia, increased glycosuria, and mild diuresis.7,8January 2014Dapagliﬂozin has demonstrated efﬁcacy and consis-
tent safety across a wide range of patient populations
with T2DM at varying stages of disease severity and
duration. Efﬁcacy of dapagliﬂozin has been established
in predominantly Western populations, when used as
monotherapy9–12 and as add-on therapy to metfor-
min,9,13 sulfonylureas,14 pioglitazone,15 sitagliptin,16
or insulin regimens.17 Previous studies in both Asian
and non-Asian populations have demonstrated similar,
linear pharmacokinetics with dapagliﬂozin over the
dose range of 2.5 to 500 mg/d and dose-related ex-
cretion of glucose in the urine over 24 hours.7,18–20 A
recent Phase II study in Japanese patients demonstrated
the beneﬁts of dapagliﬂozin monotherapy in reducing
hyperglycemia over 12 weeks, with a low risk for
hypoglycemia.21 Increased renal glucose excretion
with dapagliﬂozin is also associated with caloric loss,
resulting in decreases in weight, body fat mass, and
waist circumference.22 Both weight loss and the
observed diuretic effect with treatment are consistent
with ﬁndings of modest blood pressure reductions in the
dapagliﬂozin clinical development program.23
Due to the lower body mass index (BMI) of Asian
versus non-Asian patients with T2DM24–26 and the
observed effect of dapagliﬂozin on weight22 in
addition to ethnic differences in postprandial glucose
(PPG) regulation,27–29 it was important to investigate
the effects of dapagliﬂozin therapy in a broad Asian
population. The goal of the current study was to
present the efﬁcacy and safety ﬁndings of dapagliﬂozin
as monotherapy in drug-naive, Asian (predominantly
Chinese) patients with T2DM whose disease was
inadequately controlled with diet and exercise.PATIENTS AND METHODS
Study Design
This was a randomized, double-blind, placebo-
controlled, parallel-group, Phase III study with a
42-day lead-in period, a 24-week double-blind
treatment period, and a 28-day follow-up period
conducted between June 2010 and March 2012 at
40 sites (26 in China, 5 each in Korea and Taiwan,
and 4 in India). The study complied with the Decla-
ration of Helsinki and the International Conference
on Harmonisation/Good Clinical Practice Guideline.
It was approved by institutional review boards and
independent ethics committees for participating
centers, and is registered with ClinicalTrials.gov85
Clinical Therapeutics(NCT01095653). All participants provided written
informed consent.
Men and woman aged Z18 years with inad-
equately controlled T2DM deﬁned as a glycosylated
hemoglobin (HbA1c) levels Z7.5% and r10.5%
(Z58 and r91 mmol/mol) at the enrollment visit
andZ7.0% andr10.5% (Z53 andr91 mmol/mol)
at the lead-in day 14 visit were included in this
study. Patients were required to have a C-peptide level
Z1.0 ng/mL (0.34 nmol/L) and a BMI r45.0 kg/m2
at the enrollment visit and be drug naive (never
received prescription medication, including Chinese
traditional medicines for diabetes, or have received
prescription medication for diabetes for o24 weeks
since original diagnosis).
Full exclusion criteria are provided in Supplemental
Table I (available in the online version at http://dx.doi.
org/10.1016/j.clinthera.2013.11.002). In brief, patients
were excluded from enrollment if they had: aspartate
aminotransferase and/or alanine aminotransferase levels
43 times the upper limit of normal (ULN), serum total
bilirubin 42 mg/dL (34.2 mmol/L), serum creatinine
Z1.5 mg/dL (132.6 mmol/L) for men or Z1.4 mg/dL
(123.8 mmol/L) for women (based on guidance from the
rescue therapy [metformin] prescribing information),
hemoglobin r110 g/L for men and r100 g/L for
women, creatine kinaseZ3 times the ULN, urine albumin:
creatinine ratio 41800 mg/g, severe hypertrigly-
ceridemia (triglyceride 4800 mg/dL [9.3 mmol/L]),
urinary excretion of N-acetyl-β-D-glucosaminidase
(NAG) 484 mmol/h NAG/mmol creatinine, urinary ex-
cretion of α1 microglobulin428 mg α1 microglobulin/g
creatinine, parathyroid hormone value41.5 times the
ULN, calcium or serum phosphate values outside the
normal reference range, abnormal free T4 values, and
positive hepatitis B surface antigen or positive anti–
hepatitis C antibodies. Patients with currently unstable
or serious vascular, renal, hepatic, hematologic,
oncologic, endocrine, psychiatric, or rheumatic
diseases were also excluded.
Eligible patients ﬁrst completed a 6-week, single-
blind, placebo lead-in period in which they received
diet and exercise counseling consistent with the China
Diabetes Society recommendations. An interim visit
at lead-in day 14 to evaluate patient safety and
continued eligibility was also performed. Eligible
patients from the lead-in period with HbA1c levels
Z7.0% and r10.5% (Z53 and r91 mmol/mol)
were then randomized sequentially by using an86interactive voice response system in a blinded manner
to 1 of 3 treatment groups (in a 1:1:1 ratio, stratiﬁed
according to site): 5 or 10 mg of dapagliﬂozin or
placebo taken orally once per day before the ﬁrst meal
of the day. Changes in the blinded study medication
were not permitted during the study. The number of
patients with HbA1c levels Z7.0 and r7.4% (Z53
and r57 mmol/mol) randomized to treatment was
limited to 20% of the population maximum (ie, 76
patients). Visits were scheduled at weeks 1, 2, 4, 8, 12,
16, 20, and 24 during the double-blind period. After
the initial screening visit, patients, investigators, and
the study sponsors were blinded to treatment group
and HbA1c and urinary glucose values (including
urinary glucose:creatinine ratio).
Patients with inadequate glycemic control could
remain in the trial and receive open-label rescue
therapy with metformin (500 mg daily, titrated to
2000 mg if necessary). Criteria for inadequate glyce-
mic control requiring rescue therapy became progres-
sively more stringent over time: during weeks 4 to 12,
a central laboratory fasting plasma glucose (FPG)
measurement (conﬁrmed with a second measurement
within 3–5 days) of 4240 mg/dL (13.3 mmol/L) was
required; during weeks 12 to 24, an FPG level 4200
mg/dL (11.1 mmol/L) was required. Patients with FPG
values consistently greater than protocol-speciﬁed values
for 12 weeks despite a maximum tolerated dose of
metformin were discontinued from the study.
Clinical Measures
The primary end point was the mean change from
baseline in HbA1c level at week 24 for each dapagli-
ﬂozin group versus placebo by using the last-
observation-carried-forward (LOCF) method to im-
pute missing observations, excluding data after rescue
therapy. Secondary end points were: (1) change from
baseline in FPG at week 24; (2) change from baseline
in 2-hour PPG (after a liquid meal challenge) at week
24; (3) change from baseline in total weight at week
24; and (4) proportion of patients achieving a ther-
apeutic glycemic response, deﬁned as HbA1c levels
o7.0% (53 mmol/mol), at week 24. A sensitivity
analysis evaluated change in HbA1c according to
baseline HbA1c subgroups (o8.0% [o64 mmol/mol],
Z8.0 too9.0% [Z64–o75 mmol/mol], andZ9.0%
[Z75 mmol/mol]).
Exploratory end points included: change from base-
line at week 24 in β-cell function and insulin resistanceVolume 36 Number 1
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2 [HOMA-2]), change from baseline in waist circum-
ference at week 24, percent change from baseline in
lipids (total cholesterol, LDL-C, HDL-C, and fasting
triglyceride) at week 24, and the proportion of patients
with Z3% orZ5% reduction in total weight at week
24. The pharmacodynamic end point was the change
from baseline in spot fasting urinary glucose to
creatinine ratio at week 24.
Safety and tolerability were assessed by collating
data on adverse events (AEs) and serious AEs (SAEs)
by using preferred terms from the Medical Dictionary
for Regulatory Activities (version 15.0). (The deﬁni-
tion of an SAE is described in Supplemental Table I
available in the online version at http://dx.doi.org/10.
1016/j.clinthera.2013.11.002.) Discontinuations due
to AEs, laboratory tests (conducted at the central labo-
ratory, QLabs [Beijing, China; Mumbai, India; and
Singapore]), changes in vital signs, hypoglycemia, and
other AEs of special interest were also assessed.
Major hypoglycemia was deﬁned as symptomatic
episodes requiring external assistance due to severely
impaired consciousness or behavior, with capillary or
plasma glucose valueso54 mg/dL (o3.0 mmol/L) and
prompt recovery after glucose or glucagon adminis-
tration. Minor hypoglycemia was deﬁned as any
episode (symptomatic or asymptomatic) with a capil-
lary or plasma glucose measure o63 mg/dL (o3.5
mmol/L) that did not qualify as a major episode. Other
episodes of hypoglycemia were deﬁned as episodes
reported by the investigator that were suggestive of
hypoglycemia but did not meet the aforementioned
criteria. A prespeciﬁed list of preferred terms from the
Medical Dictionary for Regulatory Activities identiﬁed
AEs as genital infections, urinary tract infections
(UTIs), renal AEs, and volume depletion. Patients
reported safety events to investigators both sponta-
neously and in response to questions proactively posed
by the investigator at study visits.
Statistical Analysis
Sample size calculations were conducted on the
basis of anticipated differences for the primary end
point. Furthermore, for registration in China, regional
Asian studies are required to have at least 100 patients
from China in each treatment arm or at least 90%
power in the Chinese subgroup, whichever is greater.
Therefore, to detect a difference of 0.6% between
dapagliﬂozin versus placebo for changes from baselineJanuary 2014to week 24 in HbA1c level (assuming an SD of 1.1%
and at a signiﬁcance level of 0.027), 120 patients (100
from China) per treatment group were required to
provide 97% power (94% for the Chinese popula-
tion). Assuming that 5% of patients would not have a
postbaseline assessment, 126 patients per group (105
from China and 21 from other countries/regions) were
planned for randomization (378 patients in total).
Patients randomized to treatment who received at
least 1 dose of double-blind study medication and had
both a baseline and postbaseline measurement were
included in the efﬁcacy analyses. Patients who received
at least 1 dose of double-blind study medication were
included in the safety analyses. The primary end point
was tested by using Dunnett’s method at the level of
α ¼ 0.027 for each pair-wise group comparison of
dapagliﬂozin versus placebo (overall level of α ¼ 0.05).
A hierarchical closed testing procedure was used to
control the type I error rate across the primary and
secondary end points at the level of α ¼ 0.05 within
each treatment group. If the primary comparison
between a dapagliﬂozin group ﬁnding versus placebo
was signiﬁcant, statistical tests for the secondary end
points were performed for that treatment group. The
statistical testing of the secondary end points pro-
ceeded in a sequential manner; only those dapagliﬂozin
groups signiﬁcantly superior to placebo for the ﬁrst
secondary end point had statistical inference tested
versus placebo for the second secondary end point (α
¼ 0.05 level) and, if signiﬁcant, followed by the third
secondary end point, and so forth.
The continuous end points were evaluated by using
ANCOVA with treatment group as a ﬁxed effect and
the baseline value as a covariate. The assessment of
the primary end point according to baseline HbA1c
subgroups was analyzed by using an ANCOVA model
with terms for treatment group, baseline HbA1c
category, and the interaction between treatment and
baseline HbA1c category. The proportion of patients
achieving HbA1c levels o7.0% (53 mmol/mol) was
analyzed by logistic regression using methods of
Zhang et al,30 with adjustment for baseline HbA1c
levels. The proportion of patients withZ3% orZ5%
reduction in total weight was analyzed by using the
same method, with adjustment for baseline weight.
For the efﬁcacy analysis, observations after the
initiation of rescue therapy were excluded, with
these and other missing values replaced by using the
LOCF method. Safety data were summarized by using87
Clinical Therapeuticsdescriptive statistics and included data after the
initiation of rescue therapy.
RESULTS
Patients
Demographic and baseline characteristics were
balanced across treatment groups; mean age was
51.3 years, and patients had a median disease dura-
tion of 0.2 year (Table I). More male than female
patients participated in the study (65.4% vs 34.6%),Table I. Demographic and baseline characteristics.
Characteristic Plac
No. of patients 1
Age, mean (SD), y 49.9
Sex, no. (%)
Male 87
Female 45
Race, no. (%)
Chinese 117
Asian Indian 8
Korean 5
Japanese 1
Other Asian 1
Weight, mean (SD), kg 72.18
Waist circumference, mean (SD), cm 91.33
BMI, mean (SD), kg/m2 25.93
History of dyslipidemia, no. (%) 53
History of hypertension, no. (%) 54
Duration of T2DM, y
Mean (SD) 1.30
Median (range) 0.2
HbA1c, mean (SD), % 8.35
FPG, mean (SD), mg/dL (mmol/L) 167.13
(9.28
Fasting C-peptide, mean (SD), ng/mL (nmol/L) 2.63
(0.87
Seated blood pressure, mean (SD),
mm Hg
Systolic 123.5
Diastolic 78.7
BMI ¼ body mass index; T2DM ¼ type 2 diabetes mellitus; H
glucose.
*After a database lock, it was determined that this patient was
patient is actually Chinese.
88and the majority of patients were from China (89%).
Mean weight and BMI were 70.7 kg and 25.6 kg/m2,
respectively; mean waist circumference was 90.2 cm.
According to Asian deﬁnitions,31 approximately two
thirds of patients (64.9%) were overweight (BMIZ24
kg/m2) and a smaller proportion (21.4%) were obese
(BMI Z28 kg/m2). Mean HbA1c level was 8.26%
(67 mmol/mol), and mean seated systolic blood pre-
ssure (SBP) and seated diastolic blood pressure (DBP)
were 123.7 and 77.8 mm Hg, respectively, at baseline.ebo Dapagliﬂozin 5 mg Dapagliﬂozin 10 mg
32 128 133
(10.87) 53.0 (11.07) 51.2 (9.89)
(65.9) 84 (65.6) 86 (64.7)
(34.1) 44 (34.4) 47 (35.3)
(88.6) 114 (89.1) 117 (88.0)
(6.1) 8 (6.3) 9 (6.8)
(3.8) 6 (4.7) 5 (3.8)
(0.8) 0 1 (0.8)*
(0.8) 0 1 (0.8)
(13.23) 68.89 (11.43) 70.92 (11.64)
(9.65) 89.32 (8.93) 89.86 (9.02)
(3.64) 25.17 (3.29) 25.76 (3.43)
(40.2) 49 (38.3) 57 (42.9)
(40.9) 49 (38.3) 50 (37.6)
(2.0) 1.15 (2.3) 1.67 (2.8)
(0–9.9) 0.2 (0–14.7) 0.4 (0–13.0)
(0.95) 8.14 (0.74) 8.28 (0.95)
(42.79) 154.37 (31.68) 162.22 (43.30)
[2.37]) (8.57 [1.76]) (9.00 [2.40])
(1.17) 2.39 (1.39) 2.47 (1.00)
[0.39]) (0.79 [0.46]) (0.82 [0.33])
(14.7) 124.1 (13.6) 123.5 (14.7)
(8.2) 76.8 (9.0) 78.0 (8.5)
bA1c ¼ glycosylated hemoglobin; FPG ¼ fasting plasma
incorrectly entered into the study database as Japanese; the
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demia and 38.9% had a history of hypertension. (For
baseline characteristics and patient disposition of the
exclusively Chinese population, see Supplemental
Figure 1 and Supplemental Table II in the online
version at http://dx.doi.org/10.1016/j.clinthera.2013.
11.002.)
Overall, the majority of randomized patients com-
pleted the study (87.3%) (Figure 1); the most
common reasons for discontinuation were
withdrawal of consent (3.0%, 3.9%, and 2.3% in
the placebo, dapagliﬂozin 5-mg, and dapagliﬂozin 10-
mg groups, respectively), patient request (6.1%,
2.3%, and 0.8%), and AEs (0.8%, 3.1%, and
3.0%). Median exposure to study drug was 169 days
in each group. More patients discontinued or received
rescue medication for failing to achieve glycemic
targets for placebo (16.0% [95% CI, 9.9 to 22.0])
versus either dapagliﬂozin 5 mg (3.1% [95% CI, 0.6
to 5.6]) or dapagliﬂozin 10 mg (1.4% [95% CI, 0.7
to 3.4]).1179 patients enrolle
510 continued to the lea
393 randomized to receive plac
128 dapagliflo
5 mg/d
132 placebo
15 not completed:19 not completed:
3 lack of efficacy
4 AEs1 AE
5 withdrew conse
4 withdrew consent 3 requested exit
8 requested exit
1 lost to follow-up
1 poor compliance/noncompliance
113 completed 113 completed
1 other
2 no longer met
   study criteria
1 poor complianc
514 patients completed
qualification period
Figure 1. Trial profile.
January 2014Primary End Point
Dapagliﬂozin 5- and 10-mg monotherapy met the
primary end point at week 24 LOCF (Figure 2A);
adjusted mean changes from baseline in HbA1c were
1.04% and 1.11%, respectively, versus 0.29%
for placebo (Po 0.0001 for both doses). Differences
versus placebo in adjusted mean reductions from
baseline were 0.75% for dapagliﬂozin 5 mg and
0.82% for dapagliﬂozin 10 mg, suggesting that the
effect of dapagliﬂozin on HbA1c is dose related.
Sensitivity Analysis
When evaluated according to baseline HbA1c sub-
group (Figure 2B), the most pronounced effect was
observed in the highest baseline HbA1c group (Z9.0%
[75 mmol/mol]); the difference versus placebo was
1.06% (95% CI, 1.54 to 0.57) for dapagliﬂozin
5 mg and 1.32% (95% CI, 1.72 to 0.93)
for dapagliﬂozin 10 mg. The primary outcome and
sensitivity analyses according to baseline HbA1c level
were similar when the exclusively Chinese populationd
665 not completing
qualification period
603 no longer met study criteria:
48 withdrew consent
11 patient request
1 lost to follow-up
2 other
d-in period
ebo or study drug
zin 133 dapagliflozin
10 mg/d
16 not completed:
nt
117 completed
4 lost to follow-up
7 lost to follow-up
30 withdrew consent
70 no longer met study criteria:
117 not randomized:
4 poor compliance/noncompliance
3 AEs
3 other
e/noncompliance
4 AEs
3 withdrew consent
1 requested exit
2 no longer met
    study criteria
2 poor compliance/noncompliance
 the
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L. Ji et al.was analyzed separately (Supplemental Figures 2A and
2B in the online version at http://dx.doi.org/10.1016/j.
clinthera.2013.11.002).
Secondary End Points
Dapagliﬂozin was signiﬁcantly different from pla-
cebo at week 24 (LOCF) in all the secondary end
points assessed (Figures 2C–2F). The dapagliﬂozin
5- and 10-mg doses produced mean reductions from
baseline in FPG, which were signiﬁcantly greater
(–25.1 mg/dL [–1.39 mmol/L], P o 0.0001 and
–31.6 mg/dL [–1.75 mmol/L], P o 0.0001) compared
with placebo (2.5 mg/dL [0.14 mmol/L]). Reduction
from baseline in mean 2-hour PPG in response to a
liquid meal challenge was signiﬁcantly greater with
dapagliﬂozin 5 mg (–46.8 mg/dL [–2.60 mmol/L],
P o 0.0001) and 10 mg (–54.9 mg/dL [3.05 mmol/
L], P o 0.0001) compared with placebo (1.1 mg/dL
[0.06 mmol/L]). Dapagliﬂozin also resulted in signiﬁ-
cant mean reductions from baseline in total weightFigure 2. Primary and secondary end points. (A) Primary e
*Difference versus placebo (95% CI) of 0.75%
dapagliflozin (DAPA) 5 mg and 10 mg, respect
adjustment). (B) Sensitivity analysis: change in
HbA1c o8.0% (o64 mmol/mol) baseline subg
(0.77 to 0.19) and 0.36% (0.66 to 0.0
Z8.0 to o9.0% (Z64 to o75 mmol/mol) sub
0.93% (1.24 to 0.63), respectively. In HbA
1.06% (1.54 to 0.57) and 1.32% (1.72
glucose (FPG). †Difference versus placebo (95%
L (1.89 to 1.19)] and 34.2 mg/dL (40.4 to 
and 10 mg, respectively (Po 0.0001 after seque
hour postprandial glucose (PPG) after a liquid
sequential testing procedure at α ¼ 0.05. (E) Ch
CI) of 1.37 kg (2.01 to 0.73) and 1.98
respectively (P o 0.0001 after sequential testing
patients with a therapeutic glycemic response,
Analyses exclude data after rescue therapy. N is
received Z1 dose of double-blind study medi
treatment who received Z1 dose of double-blin
week 24 (last-observation-carried-forward) valu
from baseline  95% CIs derived from ANCOVA
covariate. For B, data are adjusted mean change
terms for treatment group, baseline HbA1c cate
HbA1c category. For F, data are adjusted percent
based on the methods of Zhang et al,30 with
number of patients showing a response.
January 2014(–1.64 kg for the 5-mg dose and –2.25 kg for the 10-
mg dose; P o 0.0001 for both doses) compared with
the mean reduction from baseline observed with place-
bo (–0.27 kg). The proportion of patients achieving an
HbA1c level o7.0% (53 mmol/mol) at week 24 was
signiﬁcantly greater with dapagliﬂozin 5 mg (42.6%; P
o 0.0001) and 10 mg (49.8%; Po 0.0001) compared
with placebo (21.3%). Secondary outcomes were
similar in the exclusively Chinese subgroup (Supple-
mental Figures 2C–2F in the online version at http://
dx.doi.org/10.1016/j.clinthera.2013.11.002).
Exploratory End Points
Exploratory end points are detailed in Table II.
Greater proportions of patients receiving dapagliﬂozin
10 mg and 5 mg achieved Z3% reduction from base-
line in total weight (46.0% and 42.4%, respectively)
versus placebo (15.1%). This trend was also apparent
when considering proportions achieving Z5% reduc-
tion from baseline in total weight: 29.6% and 20.8%,nd point: change in glycosylated hemoglobin (HbA1c).
(0.94 to 0.56) and 0.82% (1.01 to 0.63) for
ively (P o 0.0001 at α ¼ 0.027 applying Dunnett’s
HbA1c according to baseline HbA1c subgroups. In
roup: difference versus placebo (95% CI) of 0.48%
7) for DAPA 5 mg and 10 mg, respectively. In HbA1c
group: difference of 0.86% (1.16 to 0.56) and
1c Z9.0% (Z75 mmol/mol) subgroup: difference of
to 0.93), respectively. (C) Change in fasting plasma
CI) of 27.7 mg/dL (34.0 to 21.4) [1.54 mmol/
27.9) [1.90 mmol/L (2.24 to 1.55)] for DAPA 5 mg
ntial testing procedure at α ¼ 0.05). (D) Change in 2-
meal challenge. ‡P o 0.0001 versus placebo after
ange in total weight. §Difference versus placebo (95%
kg (2.62 to 1.34) for DAPA 5 mg and 10 mg,
procedure at α ¼ 0.05). (F) Adjusted proportion of
defined as an HbA1c level o7.0% (53 mmol/mol).
the number of patients randomized to treatment who
cation; n is the number of patients randomized to
d study medication and had nonmissing baseline and
es. For A, C, and D, data are adjusted mean change
with treatment group as effect and baseline value as a
from baseline  95% CIs derived from ANCOVA with
gory, and interaction between treatment and baseline
with 95% CIs derived from logistic regression analysis
adjustment for baseline for baseline HbA1c; x is the
91
Table II. Exploratory end points at week 24. Data are last-observation-carried-forward (LOCF) excluding data after rescue therapy.
Characteristic Placebo (N ¼ 132) Dapagliﬂozin 5 mg (N ¼ 128) Dapagliﬂozin 10 mg (N ¼ 133)
Total cholesterol
n 123 119 123
Baseline mean (SD), mg/dL 189.7 (41.3) 191.8 (59.9) 187.8 (34.1)
Adjusted mean percent change at week 24, % (95% CI)* 1.43 (4.11 to 1.33) 2.66 (5.34, 0.11) 2.28 (0.50 to 5.14)
Difference versus placebo 1.25 3.76
95% CI of difference 5.05 to 2.71 0.21 to 7.88
LDL-C
n 122 119 123
Baseline mean (SD), mg/dL 106.3 (33.8) 109.7 (37.1) 103.2 (30.3)
Adjusted mean percent change at week 24, % (95% CI)* 0.97 (5.45 to 3.73) 2.16 (6.65 to 2.54) 7.20 (2.36 to 12.26)
Difference versus placebo 1.21 8.24
95% CI of difference 7.52 to 5.53 1.39 to 15.56
HDL-C
n 123 119 123
Baseline mean (SD), mg/dL 44.1 (10.0) 46.7 (11.1) 45.7 (11.4)
Adjusted mean percent change at week 24, % (95% CI)* 4.24 (1.45 to 7.11) 9.55 (6.57 to 12.62) 11.52 (8.55 to 14.58)
Difference versus placebo 5.09 6.99
95% CI of difference 1.10 to 9.25 2.96 to 11.17
Triglycerides
n 123 120 126
Baseline mean (SD), mg/dL 227.1 (262.0) 186.1 (349.2) 205.8 (150.2)
Adjusted mean percent change at week 24, % (95% CI)* 6.95 (13.39 to 0.03) 19.11 (24.81 to 12.99) 16.47 (22.18 to 10.33)
Difference versus placebo 13.07 10.23
95% CI of difference 21.55 to 3.67 18.82 to 0.72
Urinary glucose:creatinine ratio, g/g
n 116 112 114
Baseline mean (SD) 3.59 (9.70) 3.48 (9.63) 3.49 (12.04)
Adjusted mean absolute change at week 24 (95% CI)† 0.79 (3.02 to 4.60) 26.92 (23.04 to 30.79) 34.91 (31.07 to 38.76)
Difference versus placebo 26.13 34.12
95% CI of difference 20.69 to 31.56 28.71 to 39.53
Fasting C-peptide, ng/mL
n 115 110 114
Baseline mean (SD) 2.61 (1.19) 2.35 (1.41) 2.50 (1.03)
Adjusted mean absolute change at week 24 (95% CI)† 0.03 (0.17 to 0.12) 0.36 (0.51 to 0.21) 0.40 (0.54 to 0.25)
Difference versus placebo 0.34 0.37
95% CI of difference 0.54 to 0.13 0.57 to 0.17
Waist circumference, cm
n 118 114 118
Baseline mean (SD) 91.2 (9.7) 89.1 (9.1) 89.9 (8.8)
Adjusted mean absolute change at week 24 (95% CI)† 0.72 (1.50 to 0.06) 2.77 (3.56 to 1.97) 2.20 (2.98 to 1.42)
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Table II (continued).
Characteristic Placebo (N ¼ 132) Dapagliﬂozin 5 mg (N ¼ 128) Dapagliﬂozin 10 mg (N ¼ 133)
Difference versus placebo 2.05 1.48
95% CI of difference 3.17 to 0.93 2.59 to 0.38
HOMA-2 β-cell function, %
n 114 109 113
Baseline mean (SD) 56.9 (30.5) 53.9 (25.0) 56.1 (22.9)
Adjusted mean absolute change at week 24 (95% CI)† 1.05 (2.66 to 4.76) 10.49 (6.69 to 14.28) 12.74 (9.02 to 16.47)
Difference versus placebo 9.44 11.69
95% CI of difference 4.13 to 14.74 6.44 to 16.95
HOMA-2 insulin sensitivity, %
n 114 109 113
Baseline mean (SD) 52.8 (24.0) 59.4 (22.5) 52.9 (20.7)
Adjusted mean absolute change at week 24 (95% CI)† 0.16 (4.13 to 3.82) 10.05 (5.96 to 14.13) 15.48 (11.49 to 19.48)
Difference versus placebo 10.20 15.64
95% CI of difference 4.48 to 15.92 10.01 to 21.27
Proportion of patients with Z3% reduction in total weight, %
n 132 128 128
Baseline mean weight, kg 72.2 68.9 70.8
Proportion (adjusted for baseline weight) at week 24, % (95% CI)‡ 15.1 (9.0 to 21.3) 42.4 (33.8 to 50.9) 46.0 (37.4 to 54.6)
Difference versus placebo 27.2 30.9
95% CI of difference 16.7 to 37.8 20.3 to 41.4
Proportion of patients with Z5% reduction in total weight, %
n 132 128 128
Baseline mean weight, kg 72.2 68.9 70.8
Proportion (adjusted for baseline weight) at week 24, % (95% CI)‡ 5.6 (1.8 to 9.4) 20.8 (13.7 to 27.9) 29.6 (21.8 to 37.5)
Difference versus placebo 15.2 24.0
95% CI of difference 7.2 to 23.2 15.3 to 32.8
N ¼ number of patients randomized to treatment who received Z1 dose of double-blind study medication; n ¼ number of patients randomized to treatment who
received Z1 dose of double-blind study medication with nonmissing baseline and week 24 LOCF values; HOMA-2 ¼ homeostasis model assessment version 2.
*Derived from ANCOVA model for (log [week 24 value]  log [baseline value]) for each end point with treatment group as an effect and log [baseline value] as a
covariate.
†Derived from ANCOVA model with treatment group as an effect and baseline value as a covariate.
‡Proportion analyzed by using the methods of Zhang et al,30 with adjustment for baseline total weight. Measures for urinary glucose:creatinine ratio were derived
from a urinary spot-check performed in the morning fasting state.
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Clinical Therapeuticsrespectively, versus 5.6% with placebo. The effect of
treatment on patient lipid proﬁles was also assessed.
For placebo, dapagliﬂozin 5 mg, and dapagliﬂozin 10
mg, respectively, week 24 adjusted mean percent
changes from baseline were 1.43%, 2.66%, and
2.28% for total cholesterol; 0.97%, 2.16%, and
7.20% for LDL-C; 4.24%, 9.55%, and 11.52% for
HDL-C; and 6.95%, 19.11%, and 16.47% for
triglycerides. Other exploratory end points, including
waist circumference, HOMA-2 β-cell function, and
HOMA-2 insulin sensitivity, are shown in Table II.
Findings were similar when the exclusively Chinese
population was considered (Supplemental Table III in
the online version at http://dx.doi.org/10.1016/j.
clinthera.2013.11.002).
Pharmacodynamic End Point
Dapagliﬂozin treatment produced a dose-related
increase in mean urinary glucose:creatinine ratio,
consistent with its mechanism of action (Table II).
Adjusted absolute mean change at week 24 was 0.79
g/g for placebo, 26.92 g/g for dapagliﬂozin 5 mg, and
34.91 g/g for dapagliﬂozin 10 mg.
Safety and Tolerability
Overall, dapagliﬂozin was well tolerated (Table III).
AEs and SAEs were balanced across treatment groups.
No deaths occurred during the 24-week double-blind
period, no major episodes of hypoglycemia were re-
ported, and no patient discontinued the study due to
hypoglycemia. Hypoglycemic events (minor or other)
were reported in 1 patient each in the 5- and 10-mg
dapagliﬂozin groups and 2 patients in the placebo group.
Overall, few patients experienced AEs of genital
infection or UTI, although proportions were higher
in the dapagliﬂozin versus placebo groups: 0.8%,
3.1%, and 4.5% experienced genital infections in the
placebo and dapagliﬂozin 5- and 10-mg groups,
respectively, and 3.0%, 3.9%, and 5.3% experienced
UTIs. All reported events were of mild or moderate
intensity. One patient (in the dapagliﬂozin 5-mg
group) discontinued the study due to a genital
infection and UTI, both of moderate intensity. Both
events resolved after antibiotic treatment. One pa-
tient (in the dapagliﬂozin 10-mg group) experienced
an SAE (urethritis of moderate intensity). The event
resolved after treatment with an antibiotic and an
antifungal agent, and the patient continued in the
study. No patient experienced kidney infection or94pyelonephritis. An SAE of pancreatic carcinoma was
observed in 1 patient in the dapagliﬂozin 5-mg group;
no other neoplasms were observed in this study.
Events of renal impairment occurred in 6 patients
overall (1.5%); 2 patients in the placebo group, 1
patient in the dapagliﬂozin 5-mg group, and 3 patients
in the dapagliﬂozin 10-mg group. There were no
episodes of renal failure reported during the 24-week
double-blind period. All the renal impairment events
were of mild intensity, and none were serious or
resulted in discontinuation. Five of 6 of these AEs were
reported due to asymptomatic, transient NAG increases
that did not meet protocol-speciﬁed criteria for either re-
testing or study discontinuation. None of these patients
had ﬁndings outside of normal limits for any of the
traditional markers of renal function (serum creatinine,
cystatin C, blood urea nitrogen, and estimated glomer-
ular ﬁltration rate). Mean estimated glomerular ﬁltration
rate was minimally increased at week 24 across all
treatment groups, although these changes were not
considered clinically meaningful: 0.8, 2.3, and 0.9 mL/
min/1.73 m2 for placebo, dapagliﬂozin 5 mg, and
dapagliﬂozin 10 mg, respectively.
Changes from baseline in other selected laboratory
parameters are shown in Table IV. At week 24, dapag-
liﬂozin treatment was associated with small increases in
mean hematocrit and mean blood urea nitrogen levels
and a decrease in mean uric acid levels. Values for these
parameters at 12 weeks versus those at 24 weeks
showed no evidence of progressive change with dapag-
liﬂozin therapy. There were no clinically relevant mean
changes from baseline in any liver function test results.
Change from baseline at week 24 in mean seated
SBP was 0.8 mm Hg in the placebo group, 1.2 mm
Hg in the dapagliﬂozin 5-mg group, and 2.3 mm Hg
in the dapagliﬂozin 10-mg group (Table III). Change
from baseline at week 24 in mean seated DBP was 0.4,
1.3, and 1.6 mm Hg in the placebo, dapagliﬂozin
5-mg, and dapagliﬂozin 10-mg groups. No clinically
meaningful mean changes from baseline were ob-
served in supine, standing, orthostatic, or seated heart
rate. Proportions of patients with a vital sign exami-
nation indicating orthostatic hypotension were low at
week 24 in the placebo group (1 of 107 [0.9%]) and
the dapagliﬂozin 5-mg (5 of 103 [4.9%]) and 10-mg
(2 of 107 [1.9%]) groups. No patient experienced an
AE of volume depletion during the study.
Safety and laboratory outcomes were similar
when the exclusively Chinese population wasVolume 36 Number 1
Table III. Overall summary of patients with an adverse event (AE), AEs with frequency Z2% in any group and higher in dapagliflozin versus
placebo groups, AEs of special interest, and blood pressure measurements, including data after rescue therapy.
Preferred Term Placebo (N ¼ 132) Dapagliﬂozin 5 mg (N ¼ 128) Dapagliﬂozin 10 mg (N ¼ 133)
Overall summary of no. (%) of patients with an AE
Z1 AE 84 (63.6) 79 (61.7) 81 (60.9)
AE leading to discontinuation 1 (0.8) 3 (2.3) 3 (2.3)
Z1 SAE 2 (1.5) 5 (3.9) 4 (3.0)
No. (%) of AEs with frequency Z2% in any group (by MedDRA
preferred term) and higher in dapagliﬂozin versus placebo groups
Nasopharyngitis 5 (3.8) 7 (5.5) 4 (3.0)
Urinary tract infection 4 (3.0) 5 (3.9) 5 (3.8)
Toothache 2 (1.5) 4 (3.1) 3 (2.3)
Increased N-acetyl-β-D-glucosaminidase 2 (1.5) 3 (2.3) 3 (2.3)
Diarrhea 2 (1.5) 3 (2.3) 3 (2.3)
Thrombocytopenia 0 5 (3.9) 3 (2.3)
Diabetic nephropathy 2 (1.5) 2 (1.6) 3 (2.3)
Back pain 1 (0.8) 1 (0.8) 4 (3.0)
Constipation 1 (0.8) 2 (1.6) 3 (2.3)
Renal impairment 2 (1.5) 1 (0.8) 3 (2.3)
Cough 1 (0.8) 4 (3.1) 1 (0.8)
Increased blood creatine phosphokinase 0 3 (2.3) 2 (1.5)
Urgency of micturition 1 (0.8) 0 3 (2.3)
Gastritis 0 3 (2.3) 1 (0.8)
No. (%) of patients with an AE of special interest
Z1 hypoglycemic event* 2 (1.5) 1 (0.8) 1 (0.8)
AEs of genital infection† 1 (0.8) 4 (3.1) 6 (4.5)
Balanoposthitis 0 1 (0.8) 2 (1.5)
Genital infection 0 2 (1.6) 1 (0.8)
Posthitis 0 0 1 (0.8)
Vaginal infection 0 0 1 (0.8)
Vulvovaginal mycotic infection 0 0 1 (0.8)
Fungal genital infection 1 (0.8) 1 (0.8) 0
AEs of urinary tract infection† 4 (3.0) 5 (3.9) 7 (5.3)
Urinary tract infection 4 (3.0) 5 (3.9) 5 (3.8)
Urethritis 0 0 2 (1.5)
Renal impairment†,‡ 2 (1.5) 1 (0.8) 3 (2.3)
Blood pressure, mm Hg
Baseline mean (SD) seated systolic blood pressure n ¼ 132 123.5 (14.7) n ¼ 128 124.1 (13.6) n ¼ 133 123.5 (14.7)
Adjusted mean (SE) absolute change at week 24 n ¼ 113 0.8 (1.2) n ¼ 112 1.2 (1.2) n ¼ 114 2.3 (1.1)
Baseline mean (SD) seated diastolic blood pressure n ¼ 132 78.7 (8.2) n ¼ 128 76.8 (9.0) n ¼ 133 78.0 (8.5)
Adjusted mean (SE) absolute change at week 24 n ¼ 113 0.4 (0.8) n ¼ 112 1.3 (0.9) n ¼ 114 1.6 (0.8)
N ¼ number of treated patients; no. ¼ number of patients evaluated at speciﬁed time point; SAE ¼ serious AE.
*None led to study discontinuation.
†Based on deﬁnitive (prespeciﬁed) Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (version 15.0).
‡No events of renal failure were observed during the 24-week double-blind treatment period.
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Table IV. Laboratory values of interest: change from baseline at weeks 12 and 24, including data after rescue
therapy.
Variable
Placebo
(N ¼ 132)
Dapagliﬂozin 5 mg
(N ¼ 128)
Dapagliﬂozin 10 mg
(N ¼ 133)
Hematocrit, %
Baseline n ¼ 132 n ¼ 128 n ¼ 133
Mean (SD) 43.67 (4.03) 43.73 (3.69) 43.93 (4.32)
Change at week 12 n ¼ 121 n ¼ 119 n ¼ 119
Mean (SE) 0.20 (0.20) 1.60 (0.22) 1.72 (0.20)
Change at week 24 n ¼ 112 n ¼ 112 n ¼ 112
Mean (SE) 0.50 (0.25) 0.79 (0.20) 1.05 (0.20)
Serum creatinine, mg/dL
Baseline n ¼ 132 n ¼ 128 n ¼ 133
Mean (SD) 0.82 (0.16) 0.83 (0.16) 0.84 (0.20)
Change at week 12 n ¼ 123 n ¼ 119 n ¼ 121
Mean (SE) 0.021 (0.016) 0.003 (0.007) 0.004 (0.008)
Change at week 24 n ¼ 113 n ¼ 112 n ¼ 113
Mean (SE) 0.008 (0.008) 0.014 (0.008) 0.009 (0.009)
Estimated GFR, mL/min/1.73 m2
Baseline n ¼ 132 n ¼ 128 n ¼ 133
Mean (SD) 94.1 (17.7) 91.6 (17.1) 91.7 (20.2)
Change at week 12 n ¼ 123 n ¼ 119 n ¼ 121
Mean (SE) 1.0 (1.27) 0.5 (0.97) 0.8 (1.07)
Change at week 24 n ¼ 113 n ¼ 112 n ¼ 113
Mean (SE) 0.8 (1.06) 2.3 (1.06) 0.9 (0.98)
Blood urea nitrogen, mg/dL
Baseline n ¼ 132 n ¼ 128 n ¼ 133
Mean (SD) 14.3 (3.4) 15.1 (3.9) 15.5 (4.0)
Change at week 12 n ¼ 123 n ¼ 119 n ¼ 121
Mean (SE) 0.18 (0.29) 1.64 (0.36) 1.15 (0.33)
Change at week 24 n ¼ 113 n ¼ 112 n ¼ 113
Mean (SE) 0.46 (0.33) 1.99 (0.41) 1.80 (0.39)
Uric acid, mg/dL
Baseline n ¼ 132 n ¼ 128 n ¼ 133
Mean (SD) 5.4 (1.6) 5.2 (1.2) 5.0 (1.3)
Change at week 12 n ¼ 123 n ¼ 119 n ¼ 121
Mean (SE) 0.04 (0.10) 0.53 (0.09) 0.41 (0.08)
Change at week 24 n ¼ 113 n ¼ 112 n ¼ 113
Mean (SE) 0.04 (0.11) 0.71 (0.09) 0.42 (0.10)
N ¼ number of treated patients; n ¼ number of patients evaluated at speciﬁed time point; GFR ¼ glomerular ﬁltration rate.
Clinical Therapeuticsconsidered (Supplemental Tables IV and V in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2013.11.002).96DISCUSSION
The efﬁcacy and safety ﬁndings observed in this study
are similar to those in other studies of SGLT2Volume 36 Number 1
L. Ji et al.inhibitor treatment as monotherapy in non-Asian
populations. In a Phase III study of dapagliﬂozin as
monotherapy in treatment-naive patients enrolled
from the United States, Canada, Mexico, and Russia,
mean HbA1c reductions from baseline at week 24
were 0.23% with placebo, 0.77% with dapagli-
ﬂozin 5 mg, and 0.89% with dapagliﬂozin 10 mg,
with no major hypoglycemic episodes observed.10 In
the current study of drug-naive Asian patients with
T2DM and inadequate glycemic control with diet and
exercise, dapagliﬂozin achieved the primary end point
of statistically signiﬁcant mean reductions in HbA1c at
week 24 versus placebo; reductions with dapagliﬂozin
5 and 10 mg were 1.04% and 1.11%, respectively,
versus 0.29% with placebo.
In both studies, HbA1c lowering was seen as early as
week 4, the ﬁrst time point examined.10 The difference
in HbA1c reduction at week 24 between the 2 studies
may be accounted for, at least in part, by a greater mean
HbA1c level at baseline in the current study (8.26%)
versus the previous Western population study (7.92%).
This suggestion is supported by the sensitivity analysis
presented here, which demonstrates that although
HbA1c reductions occurred across all baseline HbA1c
subgroups with dapagliﬂozin, greater reductions were
observed in the higher baseline HbA1c subgroups. The
proportion of patients achieving HbA1c levels o7.0%
(53 mmol/mol) was signiﬁcantly greater in the
dapagliﬂozin 5- and 10-mg groups versus the placebo
group in this study (43% and 50% vs 21%, respec-
tively), consistent with the ﬁndings in the Western
population study (44% and 51% vs 32%).
Dose-dependent mean reductions in the secondary
end points of FPG and 2-hour PPG (after a liquid meal
challenge) were signiﬁcantly greater for dapagliﬂozin
compared with placebo in these analyses. Adjusted
mean change from baseline in FPG after 24 weeks of
therapy in the previous study of dapagliﬂozin in a
Western population (4.1, 24.1, and 28.8 mg/dL
for placebo, dapagliﬂozin 5 mg, and dapagliﬂozin 10
mg, respectively)10 are comparable with ﬁndings
reported in the current study (2.5, 25.1, and
31.6 mg/dL). It has previously been demonstrated
that PPG regulation may vary according to ethnicity
of the patient population.27–29 In this study of Asian
patients, dapagliﬂozin decreased 2-hour PPG levels
after a liquid meal challenge, as reported previously
with dapagliﬂozin treatment in non-Asian patient
populations.14,32,33January 2014The mean weight reductions of 1.64 and 2.25
kg observed for dapagliﬂozin 5 mg and 10 mg in the
current study (and 0.27 kg for placebo) are lower
than the mean weight loss observed in the study of
dapagliﬂozin in the Western population: 2.83 and
3.16 kg, respectively, and 2.20 kg for placebo.
However, the baseline patient characteristics in the
current study are typical of an Asian population,24–26
with mean weight and BMI lower than observations
from comparable, non-Asian patients with T2DM.10,34
Despite this lower mean baseline weight, use of
dapagliﬂozin resulted in signiﬁcant reductions in
glycemia and mean weight versus placebo throughout
the study, suggesting that it is an effective therapy in
Asian populations with lower mean BMI, similar to
previous ﬁndings in Western populations with higher
BMIs.9,10,13–15,17 Importantly, no safety or tolerability
issues were identiﬁed with dapagliﬂozin-induced
weight loss in this Asian population with lower mean
BMI and T2DM; the safety proﬁle in general was
consistent with the overall dapagliﬂozin clinical pro-
gram, which comprised both Western and Asian
patients. A previous study of dapagliﬂozin in healthy
Chinese subjects has also demonstrated similar phar-
macodynamics and pharmacokinetics compared with
non-Chinese subjects.20 Taken together, these obser-
vations suggest that the overall effect of dapagliﬂozin
is comparable in Asian and non-Asian populations.
Dapagliﬂozin induces weight loss via caloric loss
from glycosuria. A study by Bolinder et al22 found
that the decrease in total weight observed with
dapagliﬂozin was predominantly through reduced
total body fat mass, both visceral adipose tissue and
subcutaneous adipose tissue. The improved β-cell
function and increases in mean insulin sensitivity
observed in our study are also consistent with weight
loss and relief of glucotoxicity, and in line with
ﬁndings from clamp studies.35
AEs were balanced across groups in this Phase III
study, with few patients experiencing AEs or SAEs
leading to discontinuation, and no deaths observed.
Because SGLT2 inhibition is independent of insulin
secretion or action, dapagliﬂozin has a low intrinsic
propensity to cause hypoglycemia.36 In the current
study, hypoglycemia was uncommon across treatment
groups; there were no episodes of major hypoglycemia,
and no events led to discontinuation. Proportions of
patients experiencing genital infections and UTIs were
low overall, although more common with dapagliﬂozin97
Clinical Therapeuticsversus placebo; none of the events was considered
severe, only 1 dapagliﬂozin patient (10-mg group)
discontinued treatment, and there were no reports of
pyelonephritis. The relative risk of genital infections and
UTIs is increased in patients with diabetes in general,
potentially due to inadequate glycemic control, changes
in immune function, or occurrence of glycosuria.37–41
The balance of evidence from clinical studies to date
suggests that SGLT2 inhibitors increase the incidence of
genital infections42,43; the relationship to UTI incidence
is less certain, with additional long-term studies required
to address this issue. No AEs of renal failure were
reported in this study, and there was no evidence of an
adverse impact on renal function. Reductions from
baseline in mean seated SBP and DBP were observed
with dapagliﬂozin, without an increase in the proportion
of patients with orthostatic hypotension, dehydration,
or hypovolemia.
The majority of patients analyzed were resident in
China; when the Chinese subpopulation was analyzed
exclusively, efﬁcacy and safety ﬁndings similar to the
overall study population were observed. This high
proportion of Chinese patients, and hence the general-
izability of these ﬁndings to other Asian populations,
may be considered a limitation of this study. How-
ever, similar efﬁcacy and safety observations have
recently been reported for dapagliﬂozin as monother-
apy in a Phase II trial of 279 Japanese patients,21
supporting the robustness of the ﬁndings in the
current study.
CONCLUSIONS
In this study of drug-naive Asian patients, dapagliﬂozin
as monotherapy was safe and effective in improving
glycemic parameters, with low rates of hypoglycemia
and the additional beneﬁt of weight loss. These ﬁndings
are consistent with previous studies of dapagliﬂozin in
predominantly Western populations.
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Supplemental Figure 1. Trial profile of the exclusively Chinese population.
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Supplemental Figure 2. Primary and secondary end points in the exclusively Chinese population. (A) Primary end
point: change in glycosylated hemoglobin (HbA1c). *Difference versus placebo (95% CI)
of 0.70% (0.90 to 0.49) and 0.80% (1.01 to 0.60) for dapagliflozin (DAPA) 5
mg and 10 mg, respectively. (B) Sensitivity analysis: change in HbA1c according to
baseline HbA1c subgroups. In HbA1c o8.0% (o64 mmol/mol) baseline subgroup:
difference versus placebo (95% CI) of 0.52% (0.83 to 0.21) and 0.39% (0.70 to
0.08) for DAPA 5 mg and 10 mg, respectively. In HbA1c Z8.0 to o9.0% (Z64 to
o75 mmol/mol): difference of 0.85% (1.17 to 0.54) and 0.99% (1.32 to
0.66), respectively. In HbA1c Z9.0% (Z75 mmol/mol) subgroup: difference of
0.68% (1.19 to 0.17) and 1.18% (1.61 to 0.75), respectively. (C) Change
in fasting plasma glucose (FPG). †Difference versus placebo (95% CI) of 26.7 mg/dL
(33.7 to 19.8) [1.48 mmol/L (1.87 to 1.10)] and 34.8 mg/dL (41.8 to
27.9) [1.93 mmol/L (2.32 to 1.55)] for DAPA 5 mg and 10 mg, respectively. (D)
Change in 2-hour postprandial glucose (PPG) after a liquid meal challenge. (E) Change
in total weight. §Difference versus placebo (95% CI) of 1.21 kg (1.92 to 0.50) and
2.10 kg (2.80 to 1.39) for DAPA 5 mg and 10 mg, respectively. (F) Adjusted
proportion of patients with a therapeutic glycemic response, defined as an HbA1c level
o7.0% (53 mmol/mol). Analyses exclude data after rescue therapy. N is the number of
randomized patients from China who received Z1 dose of double-blind study
medication; n is the number of randomized patients from China who received Z1 dose
of double-blind study medication with nonmissing baseline and week 24 (last-observa-
tion-carried-forward) values. For A, C, and D, data are adjusted mean change from
baseline  95% CIs derived from ANCOVA, with treatment group as effect and baseline
value as a covariate. For B, data are adjusted mean change from baseline  95% CIs
derived from ANCOVA with terms for treatment group, baseline HbA1c category, and
interaction between treatment and baseline HbA1c category. For F, data are adjusted
percent with 95% CIs derived from logistic regression analysis based on the methods of
Zhang et al,30 with adjustment for baseline for baseline HbA1c; x is the number of
patients showing a response.
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Supplemental Table I. Full exclusion criteria and definition of serious adverse events.
Exclusion criteria
 History of diabetes insipidus
 Symptoms of poorly controlled diabetes that would preclude participation in this trial, including but not limited to, marked polyuria and polydipsia with410% weight loss during the
3 months before enrollment
 History of diabetic ketoacidosis or hyperosmolar nonketotic coma
 History of bone fracture secondary to diagnosed severe osteoporosis
 Severe uncontrolled hypertension deﬁned as SBP Z180 mm Hg and/or DBP Z110 mm Hg
 Any of the following cardiovascular/vascular diseases within 6 months of the enrollment visit:
— Myocardial infarction
— Cardiac surgery or revascularization (coronary artery bypass graft/percutaneous transluminal coronary angioplasty)
— Unstable angina
— Unstable congestive heart failure
— Congestive heart failure New York Heart Association class III or IV
— Transient ischemic attack or signiﬁcant cerebrovascular disease
— Unstable or previously undiagnosed arrhythmia
 History of unstable or rapidly progressing renal disease
 Conditions of congenital renal glycosuria
 Signiﬁcant hepatic disease, including but not limited to, chronic active hepatitis and/or severe hepatic insufﬁciency
 Documented history of hepatotoxicity with any medication
 Documented history of severe hepatobiliary disease
 History of hemoglobinopathy, with the exception of sickle cell trait or thalassemia minor, or chronic or recurrent hemolysis
 Donation of blood or blood products to a blood bank, blood transfusion, or participation in a clinical study requiring withdrawal of4400 mL of blood during the 6 weeks before the
enrollment visit
 Malignancy within 5 years of the enrollment visit (with the exception of treated basal cell or treated squamous cell carcinoma)
 Known immunocompromised status, including but not limited to, individuals who had undergone organ transplantation or who were positive for HIV
 Allergies or contraindication to the contents of dapagliﬂozin tablets or metformin
 Administration of any antidiabetic therapy, including Chinese traditional medicine, for 414 days (consecutive or not) during the 12 weeks before enrollment
— In addition, administration of any antidiabetic therapy, including Chinese traditional medicine, other than any previously speciﬁed, at any dose, at any time during the 4 weeks
before the enrollment visit, was an exclusion criterion
 Replacement or chronic systemic corticosteroid therapy, deﬁned as any dose of systemic corticosteroid taken for 44 weeks within 3 months before enrollment visit
 History of bariatric surgery or lap-band procedure
 Administration of sibutramine, phentermine, orlistat, rimonabant, benzphetamine, diethylpropion, methamphetamine, and/or phendimetrazine within 30 days of enrollment visit
 Administration of (Chinese) traditional therapies after enrollment in the study that have renal toxic effects (aristolochic acid), including but not limited to:
— Manchurian Dutchman’s pipe stem/guan-mu-tong (Caulis aristolochiae manshuriensis)
— Slender Dutchman’s pipe root/Radix Aristolochiae/Qing mu xiang
— Fangchi root/Radix Aristolochiae/Ma dou ling
— Wooly Dutchman’s pipe herb/Herba Aristolochiae Mollissimae/Xun gu feng
— Dutchman’s pipe vine/Caulis Aristolochiae/Tian xian teng
 Any subject who, in the judgment of the investigator, was at risk for dehydration or volume depletion that might affect the interpretation of efﬁcacy or safety data
 Any subject who was currently abusing alcohol or other drugs or had done so within the last 6 months
 Previous participation in a clinical trial with dapagliﬂozin and/or any other SGLT2 inhibitors
 Administration of any other investigational drug within 30 days of planned enrollment to this study
Serious adverse event
 A serious adverse event was deﬁned as an adverse event that was fatal, life-threatening, required in-patient hospitalization or prolonged an existing hospitalization, resulted in
persistent or signiﬁcant disability or incapacity, was cancer, was a congenital anomaly/birth defect, resulted in the development of drug dependency or drug abuse, or was an
important medical event that jeopardized the patient or required intervention to prevent a serious outcome
SBP ¼ systolic blood pressure; DBP ¼ diastolic blood pressure; SGLT2 ¼ renal sodium-glucose cotransporter 2.
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Supplemental Table II. Demographic and baseline characteristics of the exclusively Chinese population.
Characteristic Placebo
Dapagliﬂozin
5 mg
Dapagliﬂozin
10 mg
No. of patients 110 106 110
Age, mean (SD), y 49.9 (11.04) 53.4 (11.24) 51.5 (10.10)
Sex, no. (%)
Male 75 (68.2) 67 (63.2) 73 (66.4)
Female 35 (31.8) 39 (36.8) 37 (33.6)
Race, no. (%)
Chinese 110 (100) 106 (100) 109 (99.1)
Japanese 0 0 1 (0.9)*
Weight, mean (SD), kg 72.38 (13.42) 68.18 (10.22 ) 70.60 (11.46)
Waist circumference, mean (SD), cm 91.04 (9.53) 88.64 (8.15) 89.09 (8.71)
BMI, mean (SD), kg/m2 25.71 (3.64) 24.90 (2.96) 25.48 (3.08)
History of dyslipidemia, no. (%) 43 (39.1) 37 (34.9) 46 (41.8)
History of hypertension, no. (%) 46 (41.8) 40 (37.7) 39 (35.5)
Duration of T2DM, y
Mean (SD) 1.36 (2.1) 1.17 (2.4) 1.65 (2.8)
Median (range) 0.20 (0–9.9) 0.15 (0–14.7) 0.30 (0–13.0)
HbA1c, mean (SD), % 8.32 (0.95) 8.17 (0.73) 8.26 (0.97)
FPG, mean (SD), mg/dL (mmol/L) 167.09 (43.25) 156.24 (31.84) 162.50 (44.97)
(9.27 [2.40]) (8.67 [1.77]) (9.02 [2.50])
Fasting C-peptide, mean (SD), ng/mL (nmol/L) 2.67 (1.20) 2.36 (1.44) 2.37 (0.93)
(0.88 [0.40]) (0.78 [0.48]) (0.78 [0.31])
Seated systolic blood pressure, mean (SD), mm Hg 123.9 (15.38) 123.8 (13.78) 123.1 (15.17)
Seated diastolic blood pressure, mean (SD), mm Hg 78.9 (8.53) 75.8 (8.72) 77.2 (7.92)
BMI ¼ body mass index; T2DM ¼ type 2 diabetes mellitus; HbA1c ¼ glycosylated hemoglobin; FPG ¼ fasting plasma
glucose.
*After a database lock, it was determined that this patient was incorrectly entered into the study database as Japanese; the
patient is actually Chinese.
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Supplemental Table III. Exploratory end points at week 24. Data are last-observation-carried-forward (LOCF), excluding data after rescue
therapy, in the exclusively Chinese population.
Characteristic Placebo (N ¼ 110) Dapagliﬂozin 5 mg (N ¼ 106) Dapagliﬂozin 10 mg (N ¼ 110)
Total cholesterol
n 101 99 100
Baseline mean (SD), mg/dL 191.2 (43.8) 193.3 (64.3) 189.1 (33.4)
Adjusted mean percent change at week 24, % (95% CI)* 1.96 (4.99 to 1.16) 3.29 (6.31 to 0.18) 2.12 (1.05 to 5.40)
Difference versus placebo 1.35 4.17
95% CI of difference 5.66 to 3.15 0.37 to 8.91
LDL-C
n 100 99 100
Baseline mean (SD), mg/dL 107.4 (34.9) 110.2 (39.0) 103.5 (30.2)
Adjusted mean percent change at week 24, % (95% CI)* 1.69 (6.78 to 3.67) 3.01 (8.06 to 2.31) 7.44 (1.88 to 13.31)
Difference versus placebo 1.34 9.29
95% CI of difference 8.50 to 6.38 1.38 to 17.83
HDL-C
n 101 99 100
Baseline mean (SD), mg/dL 43.7 (9.9) 47.1 (10.3) 45.8 (12.0)
Adjusted mean percent change at week 24, % (95% CI)* 3.71 (0.66 to 6.85) 8.92 (5.68 to 12.25) 12.15 (8.86 to 15.55)
Difference versus placebo 5.02 8.14
95% CI of difference 0.64 to 9.59 3.67 to 12.80
Triglycerides
n 101 100 103
Baseline mean (SD), mg/dL 232.8 (281.6) 189.6 (380.8) 210.0 (157.6)
Adjusted mean percent change at week 24, % (95% CI)* 5.94 (13.30 to 2.04) 17.77 (24.28 to 10.70) 17.03 (23.47 to 10.06)
Difference versus placebo 12.57 11.79
95% CI of difference 22.18 to 1.78 21.33 to 1.09
Urinary glucose:creatinine ratio, g/g
n 97 93 94
Baseline mean (SD) 3.20 (8.89) 3.93 (10.29) 2.58 (6.55)
Adjusted mean absolute change at week 24 (95% CI)† 1.24 (2.88 to 5.35) 28.21 (24.01 to 32.42) 36.64 (32.46 to 40.83)
Difference versus placebo 26.98 35.41
95% CI of difference 21.09 to 32.86 29.54 to 41.27
Fasting C-peptide (ng/mL)
n 96 91 94
Baseline mean (SD) 2.64 (1.23) 2.31 (1.46) 2.40 (0.95)
Adjusted mean absolute change at week 24 (95% CI)† 0 (0.15 to 0.15) 0.41 (0.56 to 0.26) 0.40 (0.55 to 0.25)
Difference versus placebo 0.41 0.40
95% CI of difference 0.62 to 0.20 0.61 to 0.19
Waist circumference, cm
n 99 95 97
Baseline mean (SD) 90.9 (9.5) 88.2 (8.1) 89.0 (8.3)
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Supplemental Table III (continued).
Characteristic Placebo (N ¼ 110) Dapagliﬂozin 5 mg (N ¼ 106) Dapagliﬂozin 10 mg (N ¼ 110)
Adjusted mean absolute change at week 24 (95% CI)† 0.62 (1.50 to 0.25) 2.67 (3.56 to 1.77) 2.31 (3.20 to 1.43)
Difference versus placebo 2.05 1.69
95% CI of difference 3.30 to 0.79 2.94 to 0.44
HOMA-2 β-cell function, %
n 96 91 94
Baseline mean (SD) 57.8 (30.6) 51.6 (23.2) 55.5 (22.6)
Adjusted mean absolute change at week 24 (95% CI)† 0.77 (3.23 to 4.76) 8.88 (4.78 to 12.99) 12.62 (8.59 to 16.65)
Difference versus placebo 8.12 11.85
95% CI of difference 2.37 to 13.86 6.18 to 17.52
HOMA-2 insulin sensitivity, %
n 96 91 94
Baseline mean (SD) 52.4 (23.7) 59.9 (22.3) 54.6 (20.4)
Adjusted mean absolute change at week 24, % (95% CI)† 0.42 (3.92 to 4.75) 11.20 (6.74 to 15.66) 16.63 (12.27 to 20.99)
Difference versus placebo 10.78 16.21
95% CI of difference 4.54 to 17.03 10.07 to 22.36
Proportion of patients with Z3% reduction in total weight, %
n 110 106 105
Baseline mean weight, kg 72.4 68.2 70.4
Proportion (adjusted for baseline weight) at week 24, % (95% CI)‡ 16.2 (9.3 to 23.1) 41.4 (32.0 to 50.7) 47.6 (38.1 to 57.1)
Difference versus placebo 25.2 31.4
95% CI of difference 13.5 to 36.8 19.6 to 43.2
Proportion of patients with Z5% reduction in total weight, %
n 110 106 105
Baseline mean weight, kg 72.4 68.2 70.4
Proportion (adjusted for baseline weight) at week 24, % (95% CI)‡ 6.8 (2.3 to 11.3) 17.7 (10.4 to 25.0) 30.5 (21.7 to 39.3)
Difference versus placebo 10.9 23.7
95% CI of difference 2.3 to 19.4 13.8 to 33.6
N ¼ number of randomized patients from China who receivedZ1 dose of double-blind study medication; n ¼ number of randomized patients from China who receivedZ1 dose of double-blind study medication
with nonmissing baseline and week 24 LOCF values; HOMA-2 ¼ homeostasis model assessment version 2.
*Derived from ANCOVA model for (log [week 24 value]  log [baseline value]) for each end point with treatment group as an effect and log [baseline value] as a covariate.
†Derived from ANCOVA model with treatment group as an effect and baseline value as a covariate.
‡Proportion analyzed by using the methods of Zhang et al,30 with adjustment for baseline total weight. Measures for urinary glucose:creatinine ratio were derived from a urinary spot-check performed in the
morning fasting state. L.
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Supplemental Table IV. Overall summary of patients with an adverse event (AE), AEs with frequency Z2% in
any group and higher in dapagliflozin versus placebo groups, AEs of special interest,
and blood pressure measurements, including data after rescue therapy, in the
exclusively Chinese population.
Preferred Term
Placebo
(N ¼ 110)
Dapagliﬂozin
5 mg
(N ¼ 106)
Dapagliﬂozin
10 mg
(N ¼ 110)
Overall summary of no. (%) of patients with an AE
Z1 AE 68 (61.8) 63 (59.4) 64 (58.2)
AE leading to discontinuation 1 (0.9) 3 (2.8) 3 (2.7)
Z1 SAE 2 (1.8) 5 (4.7) 4 (3.6)
No. (%) of AEs with frequency Z2% in any group
(by MedDRA preferred term) and higher in
dapagliﬂozin versus placebo groups
Urinary tract infection 4 (3.6) 5 (4.7) 4 (3.6)
Nasopharyngitis 2 (1.8) 4 (3.8) 3 (2.7)
Toothache 2 (1.8) 4 (3.8) 3 (2.7)
Increased N-acetyl-β-D-glucosaminidase 2 (1.8) 3 (2.8) 3 (2.7)
Diarrhea 2 (1.8) 3 (2.8) 3 (2.7)
Diabetic nephropathy 2 (1.8) 1 (0.9) 3 (2.7)
Renal impairment 2 (1.8) 1 (0.9) 3 (2.7)
Thrombocytopenia 0 3 (2.8) 3 (2.7)
Dizziness 2 (1.8) 3 (2.8) 1 (0.9)
Back pain 1 (0.9) 1 (0.9) 3 (2.7)
Cough 0 3 (2.8) 1 (0.9)
Urgency of micturition 0 0 3 (2.7)
No. (%) of patients with an AE of special interest
Z1 hypoglycemic event* 2 (1.5) 1 (0.8) 0
AEs of genital infection† 0 3 (2.8) 4 (3.6)
Genital infection 0 2 (1.9) 1 (0.9)
Posthitis 0 0 1 (0.9)
Vaginal infection 0 0 1 (0.9)
Vulvovaginal mycotic infection 0 0 1 (0.9)
Fungal genital infection 0 1 (0.9) 0
AEs of urinary tract infection† 4 (3.6) 5 (4.7) 6 (5.5)
Urinary tract infection 4 (3.6) 5 (4.7) 4 (3.6)
Urethritis 0 0 2 (1.8)
Renal impairment†,‡ 2 (1.8) 1 (0.9) 3 (2.7)
Blood pressure, mm Hg
Baseline mean (SD) seated systolic blood pressure n ¼ 110 123.9 (15.4) n ¼ 106 123.8 (13.8) n ¼ 110 123.1 (15.2)
Adjusted mean (SE) absolute change at week 24 n ¼ 95 0.6 (1.4) n ¼ 93 0.5 (1.2) n ¼ 94 1.9 (1.3)
Baseline mean (SD) seated diastolic blood pressure n ¼ 110 78.9 (8.5) n ¼ 106 75.8 (8.7) n ¼ 110 77.2 (7.9)
Adjusted mean (SE) absolute change at week 24 n ¼ 95 0.2 (1.0) n ¼ 93 0.8 (0.9) n ¼ 94 1.1 (1.0)
N ¼ number of treated patients from China; n ¼ number of patients from China evaluated at speciﬁed time point;
SAE ¼ serious AE.
*None led to study discontinuation.
†Based on deﬁnitive (prespeciﬁed) Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (version 15.0).
‡No events of renal failure were observed during the 24-week double-blind treatment period.
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Supplemental Table V. Laboratory values of interest: change from baseline at weeks 12 and 24, including
data after rescue therapy, in the exclusively Chinese population.
Characteristic
Placebo
(N ¼ 110)
Dapagliﬂozin 5 mg
(N ¼ 106)
Dapagliﬂozin 10 mg
(N ¼ 110)
Hematocrit, %
Baseline n ¼ 110 n ¼ 106 n ¼ 110
Mean (SD) 44.09 (3.97) 43.69 (3.57) 44.24 (4.39)
Change at week 12 n ¼ 102 n ¼ 99 n ¼ 97
Mean (SE) 0.20 (0.22) 1.55 (0.23) 1.78 (0.23)
Change at week 24 n ¼ 94 n ¼ 93 n ¼ 92
Mean (SE) 0.40 (0.27) 0.86 (0.22) 1.11 (0.22)
Serum creatinine, mg/dL
Baseline n ¼ 110 n ¼ 106 n ¼ 110
Mean (SD) 0.83 (0.15) 0.82 (0.16) 0.85 (0.19)
Change at week 12 n ¼ 102 n ¼ 99 n ¼ 99
Mean (SE) 0.008 (0.009) 0.013 (0.007) 0 (0.009)
Change at week 24 n ¼ 95 n ¼ 93 n ¼ 93
Mean (SE) 0.012 (0.008) 0.017 (0.008) 0.009 (0.009)
Estimated GFR, mL/min/1.73 m2
Baseline n ¼ 110 n ¼ 106 n ¼ 110
Mean (SD) 92.6 (15.8) 91.5 (16.8) 91.0 (19.8)
Change at week 12 n ¼ 102 n ¼ 99 n ¼ 99
Mean (SE) 0.7 (1.22) 2.1 (0.98) 0.4 (1.10)
Change at week 24 n ¼ 95 n ¼ 93 n ¼ 93
Mean (SE) 1.5 (1.10) 2.8 (1.13) 1.0 (1.03)
Blood urea nitrogen, mg/dL
Baseline n ¼ 110 n ¼ 106 n ¼ 110
Mean (SD) 14.5 (3.3) 15.6 (3.9) 15.7 (4.1)
Change at week 12 n ¼ 102 n ¼ 99 n ¼ 99
Mean (SE) 0.28 (0.31) 1.54 (0.40) 1.06 (0.38)
Change at week 24 n ¼ 95 n ¼ 93 n ¼ 93
Mean (SE) 0.51 (0.37) 1.95 (0.47) 1.64 (0.42)
Uric acid, mg/dL
Baseline n ¼ 110 n ¼ 106 n ¼ 110
Mean (SD) 5.6 (1.6) 5.2 (1.3) 5.0 (1.3)
Change at week 12 n ¼ 102 n ¼ 99 n ¼ 99
Mean (SE) 0.10 (0.12) 0.52 (0.10) 0.38 (0.09)
Change at week 24 n ¼ 95 n ¼ 93 n ¼ 93
Mean (SE) 0.06 (0.13) 0.74 (0.10) 0.34 (0.11)
N ¼ number of treated patients from China; n ¼ number of patients from China evaluated at speciﬁed time point; GFR ¼
glomerular ﬁltration rate.
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